{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:35:51Z","timestamp":1787582151646,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Multidrug-resistant gram-negative bacteria pose a significant global health threat, particularly among vulnerable populations, such as the elderly and immunocompromised patients. Novel \u03b2-lactam (NBL) antibiotics offer promising treatment options, but real-world evidence on their efficacy in these populations remains limited. To describe the use of NBLs in clinical practice, focusing on immunologically vulnerable patients, including those with immunosuppression due to underlying disease or immunosuppressive therapy, as well as elderly individuals. Clinical characteristics, outcomes and microbiological data were descriptively analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was conducted at two university hospitals in Milan, Italy, from 2019 to 2024. Adult patients receiving NBLs (cefiderocol, ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem\/relebactam or meropenem\/vaborbactam) were included. Immunologically vulnerable patients were identified by at least one of the following conditions: active oncological disease, solid organ transplantation, autoimmune or rheumatological disorder requiring immunosuppressive therapy, HIV infection or age &amp;gt;85\u2005years. A descriptive analysis of clinical and microbiological data was performed, and the clinical course was described using clinical and biochemical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 233 patients were included, 80 (34.3%) of whom were immunologically vulnerable; 308 NBL prescriptions were recorded. Ceftazidime\/avibactam was the most prescribed agent (61.4%). Carbapenem-resistant Klebsiella pneumoniae (50.0%) and Pseudomonas aeruginosa (41.4%) were predominant pathogens. Despite greater baseline clinical severity among non-vulnerable patients, all-cause mortality and clinical improvement at T1 were similar between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world Italian cohort spanning 5 years, NBLs were widely used in immunologically vulnerable patients, a population often underrepresented in pivotal antibiotic trials, with K. pneumoniae carbapenemase\u2013producing K. pneumoniae and P. aeruginosa as predominant pathogens. Unadjusted comparisons showed similar clinical outcomes despite greater baseline severity among non-vulnerable patients, a hypothesis-generating finding warranting confirmation in adjusted, prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag171","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:38:52Z","timestamp":1786448332000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of novel \u03b2-lactams in immunologically vulnerable patients: insights from an Italian retrospective cohort"],"prefix":"10.1093","volume":"8","author":[{"given":"Matilde","family":"Bognetti","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]},{"name":"Centre for Multidisciplinary Action in Global Health (MAGH), Department of Biomedical and Clinical Sciences (DIBIC), Luigi Sacco Hospital, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1423-7415","authenticated-orcid":false,"given":"Federico","family":"Fama","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]},{"name":"Centre for Multidisciplinary Action in Global Health (MAGH), Department of Biomedical and Clinical Sciences (DIBIC), Luigi Sacco Hospital, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Conflitti","sequence":"additional","affiliation":[{"name":"National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Brivio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]},{"name":"Centre for Multidisciplinary Action in Global Health (MAGH), Department of Biomedical and Clinical Sciences (DIBIC), Luigi Sacco Hospital, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Piscaglia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Schiavini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cossu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Vimercati","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rossin","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, Fatebenefratelli Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"De Falco","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fatebenefratelli Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pagani","sequence":"additional","affiliation":[{"name":"Microbiology Unit, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Giordana","family":"Rimoldi","sequence":"additional","affiliation":[{"name":"Microbiology Unit, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4794","authenticated-orcid":false,"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]},{"name":"Centre for Multidisciplinary Action in Global Health (MAGH), Department of Biomedical and Clinical Sciences (DIBIC), Luigi Sacco Hospital, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Colaneri","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]},{"name":"Centre for Multidisciplinary Action in Global Health (MAGH), Department of Biomedical and Clinical Sciences (DIBIC), Luigi Sacco Hospital, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Palomba","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Luigi Sacco University Hospital, Regional Center for Infectious Diseases (CeReMI) , Milan ,","place":["Italy"]},{"name":"Centre for Multidisciplinary Action in Global Health (MAGH), Department of Biomedical and Clinical Sciences (DIBIC), Luigi Sacco Hospital, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026082409540904900_dlag171-B1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2026082409540904900_dlag171-B2","author":"WHO"},{"key":"2026082409540904900_dlag171-B3","author":"European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe"},{"key":"2026082409540904900_dlag171-B4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.idc.2016.02.008","article-title":"Antibiotic-resistant infections and treatment challenges in the immunocompromised host","volume":"30","author":"Dumford","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2026082409540904900_dlag171-B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1405390","article-title":"Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant gram-negative bacterial infections in Italian intensive care units","volume":"15","author":"Scaglione","year":"2024","journal-title":"Front Microbiol"},{"key":"2026082409540904900_dlag171-B6","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/microorganisms12102052","article-title":"Immunosenescence: how aging increases susceptibility to bacterial infections and virulence factors","volume":"12","author":"Theodorakis","year":"2024","journal-title":"Microorganisms"},{"key":"2026082409540904900_dlag171-B7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040411","article-title":"Clinical characteristics and bloodstream infection pathogens by gram-negative bacteria in different aged adults: a retrospective study","volume":"103","author":"Su","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026082409540904900_dlag171-B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rce.2016.09.003","article-title":"Differential characteristics of bacteraemias according to age in a community hospital","volume":"217","author":"Toyas","year":"2017","journal-title":"Rev Clin Esp"},{"key":"2026082409540904900_dlag171-B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106806","article-title":"Bloodstream infections due to gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey","volume":"61","author":"Trecarichi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026082409540904900_dlag171-B10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3390\/antibiotics11111459","article-title":"Risk factors and outcomes for multidrug resistant Pseudomonas aeruginosa infection in immunocompromised patients","volume":"11","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2022","journal-title":"Antibiotics"},{"key":"2026082409540904900_dlag171-B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12992-025-01109-4","article-title":"Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials","volume":"21","author":"Moja","year":"2025","journal-title":"Global Health"},{"key":"2026082409540904900_dlag171-B12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jgar.2025.01.007","article-title":"Unveiling results and insights from multinational, multicenter study of prescribing patterns and effectiveness of ceftolozane\/tazobactam real-world analysis (SPECTRA)","volume":"41","author":"Soriano","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"2026082409540904900_dlag171-B13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026082409540904900_dlag171-B14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae273","article-title":"Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study","volume":"11","author":"Tumbarello","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026082409540904900_dlag171-B15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026082409540904900_dlag171-B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12877-020-01984-z","article-title":"Burden of bloodstream infection in older persons: a population-based study","volume":"21","author":"Laupland","year":"2021","journal-title":"BMC Geriatr"},{"key":"2026082409540904900_dlag171-B17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082409540904900_dlag171-B18","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026082409540904900_dlag171-B19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026082409540904900_dlag171-B20","author":"Kotton"},{"key":"2026082409540904900_dlag171-B21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjy122","article-title":"Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: implications for drug withdrawal strategies","volume":"12","author":"Ben-Horin","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026082409540904900_dlag171-B22","author":"The European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026082409540904900_dlag171-B23","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026082409540904900_dlag171-B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijid.2020.03.063","article-title":"C-reactive protein and albumin kinetics after antibiotic therapy in community-acquired bloodstream infection","volume":"95","author":"P\u00f3voa","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2026082409540904900_dlag171-B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12968\/bjon.2008.17.1.28055","article-title":"The sepsis six: helping patients to survive sepsis","volume":"17","author":"Robson","year":"2008","journal-title":"Br J Nurs"},{"key":"2026082409540904900_dlag171-B26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12879-020-05181-6","article-title":"Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology center in Western China","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2026082409540904900_dlag171-B27","author":"Iacchini"},{"key":"2026082409540904900_dlag171-B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128049","article-title":"Rapid emergence, transmission, and evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae","volume":"293","author":"Li","year":"2025","journal-title":"Microbiol Res"},{"key":"2026082409540904900_dlag171-B29","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/antibiotics12101521","article-title":"Ceftazidime\/avibactam and meropenem\/vaborbactam for the management of Enterobacterales infections: a narrative review, clinical considerations, and expert opinion","volume":"12","author":"Marino","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026082409540904900_dlag171-B30","author":"European Medicines Agency (EMA)"},{"key":"2026082409540904900_dlag171-B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107553","article-title":"Susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing Enterobacterales: low activity of cefiderocol against NDM-producing isolates","volume":"66","author":"Fax\u00e9n","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"2026082409540904900_dlag171-B32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jac\/dkae416","article-title":"Clinical impact of ceftazidime\/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study","volume":"80","author":"Tumbarello","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag171\/70770673\/dlag171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag171\/70770673\/dlag171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:54:16Z","timestamp":1787579656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag171\/8769492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag171","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag171"}}